6月19日吉利德科学宣布美国食品药品管理局(FDA)已批准吉利德注射用HIV-1衣壳抑制剂Yeztugo(来那帕韦len

智通财经
Jun 19, 2025
6月19日吉利德科学宣布美国食品药品管理局(FDA)已批准吉利德注射用HIV-1衣壳抑制剂Yeztugo(来那帕韦lenacapavir)作为HIV暴露前预防(PrEP)药物以降低35公斤及以上体重的成年人和青少年通过性行为感染HIV的风险。来那帕韦用于HIV预防尚未在中国获批。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10